Skip to contentC
Castle Biosciences Inc
C
CSTLCastle Biosciences Inc Q1 2026 · 10-Q
Revenue$83.68M$83.68M−4.9% vs Q1 2025 Net Income-$14.52M-$14.52MN/M vs Q1 2025 EPS Diluted-$0.49-$0.49N/M vs Q1 2025 Operating Income-$18,407,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Castle Biosciences Inc · CIK 1447362 · Engraved from SEC EDGAR
Free Cash Flowderived-$34,584,000N/M Margins · derivedOperating margin-22.0%+9.7 pt vs Q1 2025
Net margin-17.4%+12.0 pt vs Q1 2025
ended Mar 31, 2026 · filed May 6, 2026 · 36 d after period end